AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 35986353
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg Tribulus terrestris supplement twice daily for 2 weeks
Trial: 35986353
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules twice daily for 2 weeks
Trial: 32515119
Drug: Pentoxifylline (PTX)
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (PTX) 10 mg/kg
Trial: 34864678
Drug: Olfactory Training
RxNorm normalized name: BOS TAURUS OLFACTORY BULB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olfactory Training (OT), performed twice a day for 4 months
Trial: 34864678
Drug: Control training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control training condition, performed twice a day for 4 months
Trial: 33387346
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (positive controls with no treatment)
Trial: 36147397
Drug: Single visit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single visit root canal therapy
Trial: 36147397
Drug: Multiple visit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple visit root canal therapy
Trial: 35379296
Drug: Sequential multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential multiple ascending doses of solnatide
Trial: 34155991
Drug: Modified combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified combined program of physical therapy and ergotherapy (including PNF, balance training, upright posture correction, constraint‐induced movement therapy, dual task activities, stimulation of the affected side in daily activities, targeted therapy) for 3 months
Trial: 33845853
Drug: Wearable activity
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wearable activity tracker (Fitbit Flex) combined with digital behaviour change resources and weekly challenges delivered via Facebook
Trial: 32381562
Drug: CZP 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CZP 200 mg every 2 weeks (Q2W) full maintenance dose
Trial: 32381562
Drug: CZP 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CZP 200 mg every 4 weeks (Q4W) reduced maintenance dose
Trial: 32052925
Drug: Test warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test warfarin sodium tablet
Trial: 32052925
Drug: Reference product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference product Coumadin (2.5 mg)
Trial: 33792551
Drug: Group-based cessation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group-based cessation counseling and nicotine patches
Trial: 33730752
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate (MPH) 0.25 mg/kg
Trial: 35380718
Drug: Intravenous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron supplementation
Trial: 34048554
Drug: Delays of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delays of ≥3 days to concordant antibiotic treatment
Trial: 34048554
Drug: Delays of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delays of 1-2 days to concordant antibiotic treatment
Trial: 34048554
Drug: Delays in
RxNorm normalized name: Delayed Release Oral Granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delays in appropriate antibiotic treatment
Trial: 34775223
Drug: Immediate goal‐dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate goal‐dose enteral nutrition (IGEN)
Trial: 34775223
Drug: Gradual goal‐dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gradual goal‐dose enteral nutrition (GGEN)
Trial: 36817812
Drug: Dracocephalum extract
RxNorm normalized name: Laccocephalum mylittae whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dracocephalum extract (250 mg, twice daily for one month)
Trial: 36817812
Drug: Placebo (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (250 mg starch, twice daily for one month)
Trial: 34547006
Drug: Black rice
RxNorm normalized name: Avobenzone 30 mg in 1 mL / Ensulizole 20 mg in 1 mL / Octinoxate 20 mg in 1 mL / Octocrylene 50 mg in 1 mL TOPICAL CREAM [Black Rice Platinum Absolute Youth SPF 15]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Black rice extract (1 g/d)
Trial: 34547006
Drug: Placebo (maltodextrin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (maltodextrin, 1 g/d)
Trial: 33723806
Drug: Lemborexant 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lemborexant 25 mg
Trial: 32887793
Drug: Placebo (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (400 mg corn oil)
Trial: 35753841
Drug: Moderna COVID-19
RxNorm normalized name: Moderna COVID-19 Vaccine
DrugBank: Moderna COVID-19 Vaccine (DB15654)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderna COVID-19 Vaccine (mRNA-1273)
Trial: 33883880
Drug: Rapid intravenous
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid intravenous injection of omeprazole (group A)
Trial: 33883880
Drug: Continuous micropump
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous micropump infusion of omeprazole (group B)
Trial: 32623487
Drug: Zoledronate 5
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronate 5 mg IV
Trial: 32623487
Drug: No further
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No further active treatment
Trial: 36036760
Drug: Full-dose anticoagulation
RxNorm normalized name: Rho(D) immune globulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-dose anticoagulation
Trial: 39217573
Drug: No antiplatelet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antiplatelet therapy
Trial: 32141136
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose (6,000 U/kg) of amylase
Trial: 33002971
Drug: Early supplemental
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early supplemental parenteral nutrition
Trial: 33002971
Drug: Early total
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early total parenteral nutrition
Trial: 33002971
Drug: High-dose vasopressors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose vasopressors
Trial: 35186243
Drug: Laparoscopic radical
RxNorm normalized name: Campsis radicans flower extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laparoscopic radical surgery combined with neoadjuvant chemotherapy
Trial: 34266319
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of MIC-1, CEA, CA19-9, CA24-2 for CRC diagnosis
Trial: 36101543
Drug: Spinal cord
RxNorm normalized name: BOS TAURUS SPINAL CORD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal cord stimulation (SCS) therapy
Trial: 33186740
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus fulvestrant (500 mg)
Trial: 35168030
Drug: Equisetum arvense
RxNorm normalized name: Equisetum Arvense
DrugBank: Equisetum arvense top (DB14349)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Equisetum arvense L. (EA) 900 mg/day
Trial: 34078323
Drug: Reduced CNI
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced CNI exposure in combination with everolimus and glucocorticoids
Trial: 32728879
Drug: 1 cup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 cup of espresso coffee plus 2 cocoa-based products containing coffee, twice per day
Trial: 33245709
Drug: Liquid paraffin
RxNorm normalized name: Liquid paraffin
DrugBank: Mineral oil (DB11057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid paraffin (placebo) inhalation
Trial: 32812320
Drug: Andecaliximab 800
RxNorm normalized name: Andecaliximab
DrugBank: Andecaliximab (DB17564)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Andecaliximab 800 mg every 2 weeks in combination with gemcitabine and nab-paclitaxel
Trial: 33213288
Drug: No intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No intravenous alteplase
Trial: 34579049
Drug: Test fermented
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test fermented milk containing yogurt and Lacticaseibacillus strains (L. paracasei CNCM I‐1518 and I‐3689, L. rhamnosus CNCM I‐3690) for 28 days
Trial: 33914256
Drug: EU-bevacizumab (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EU-bevacizumab (15 mg/kg)
Trial: 34348263
Drug: Additional L-carnitine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional L-carnitine (1,500 mg/day) and rifaximin (1,200 mg/day)
Trial: 37002653
Drug: CBP quadruple
RxNorm normalized name: CBPC
DrugBank: Carbenicillin (DB00578)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CBP quadruple therapy (amoxicillin 1 g twice daily, tetracycline 500 mg three times daily, esomeprazole 20 mg twice daily, CBP 200 mg three times daily)
Trial: 37002653
Drug: BPC quadruple
RxNorm normalized name: BPC-157
DrugBank: BPC-157 (DB11882)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BPC quadruple therapy (amoxicillin 1 g twice daily, tetracycline 500 mg three times daily, esomeprazole 20 mg twice daily, BPC 240 mg twice daily)
Trial: 33116029
Drug: cream-type denture
RxNorm normalized name: ALCOHOL,DENATURED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cream-type denture adhesive
Trial: 33116029
Drug: control (saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: control (saline solution)
Trial: 34904623
Drug: HPV vaccine
RxNorm normalized name: HPV vaccine 9-valent/PF 0.5 mL INTRAMUSC VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPV vaccine
Trial: 34383535
Drug: Group mindfulness-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group mindfulness-based cognitive therapy (MBCT)
Trial: 34383535
Drug: Group supportive
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group supportive sex education and therapy (STEP)
Trial: 35965904
Drug: Intralesional tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intralesional tranexamic acid (TXA) 4 mg/mL
Trial: 35965904
Drug: Topical Kligman's
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Kligman's therapy
Trial: 35397289
Drug: Repeat infusion
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeat infusion of autologous bone marrow
Trial: 36109141
Drug: Third COVID-19
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Third COVID-19 vaccination with an mRNA vaccine
Trial: 35309844
Drug: Danzhi Xiaoyao
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danzhi Xiaoyao Powder combined with photodynamic therapy (PDT)
Trial: 33894496
Drug: 70 Gy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 70 Gy daily (QD)
Trial: 33894496
Drug: Cisplatin and
RxNorm normalized name: A micelle drug formulation composed of cisplatin and mPEG-poly(l-Glu) diblock copolymer with 1,3-propanediyl linkagecisplatin is incorporated in polymeric micelles via polymer-metal complex formation with cis-geometry of PT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin and etoposide chemotherapy with TRT regimens
Trial: 33357808
Drug: Aging Treatment
RxNorm normalized name: Similas Aging Eye Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aging Treatment Model
Trial: 32366124
Drug: Therapy (38
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapy (38 participants)
Trial: 32896022
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg Panax quinquefolius
Trial: 35368763
Drug: Kleeb Bua
RxNorm normalized name: Kleer Plex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kleeb Bua Daeng (KBD) formula, 1,000 mg twice a day for three months
Trial: 33034099
Drug: Hydrocortisone 1%
RxNorm normalized name: HYDROCORTISONE 1% OINT
DrugBank: Hydrocortisone acetate (DB14539)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrocortisone 1% ointment
Trial: 33253210
Drug: Standard antifungal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard antifungal treatment with adjunctive dexamethasone
Trial: 33253210
Drug: Standard antifungal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard antifungal treatment without adjunctive dexamethasone
Trial: 32039689
Drug: Fragrance inhalation
RxNorm normalized name: Myristica fragrans fruit
DrugBank: Myristica fragrans fruit (DB15544)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fragrance inhalation of grapefruit essential oil for 10 minutes (study 1)
Trial: 32039689
Drug: Fragrance inhalation
RxNorm normalized name: Myristica fragrans fruit
DrugBank: Myristica fragrans fruit (DB15544)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fragrance inhalation of grapefruit essential oil for 10 minutes (study 2)
Trial: 32039689
Drug: Fragrance inhalation
RxNorm normalized name: Myristica fragrans fruit
DrugBank: Myristica fragrans fruit (DB15544)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fragrance inhalation of grapefruit essential oil (last 5 minutes of inhalation)
Trial: 32608134
Drug: ARE0 (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARE0 (0 g kg-1)
Trial: 32608134
Drug: ARE20 (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARE20 (20 g kg-1)
Trial: 32608134
Drug: ARE50 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARE50 (50 g kg-1)
Trial: 32608134
Drug: ARE80 (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARE80 (80 g kg-1)
Trial: 33060555
Drug: Regular scheduled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular scheduled ibuprofen (10 mg/kg per dose, maximum 600 mg every 6 hours)
Trial: 33060555
Drug: Pro re
RxNorm normalized name: Blistex Pro Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pro re nata (PRN) ibuprofen
Trial: 33060555
Drug: Regular scheduled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular scheduled ibuprofen
Trial: 34456194
Drug: ACTH administration
RxNorm normalized name: ACTH
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ACTH administration (3 times daily for 7 days)
Trial: 32991232
Drug: Cardiac rehabilitation
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiac rehabilitation group (CR) with standard medical treatments and exercise-based cardiac rehabilitation
Trial: 32991232
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with standard medical treatments without exercise
Trial: 33129628
Drug: Dyadic intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dyadic intervention to improve communication (4 weekly sessions)
Trial: 37419144
Drug: Amikacin liposome
RxNorm normalized name: AMIKACIN LIPOSOME
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amikacin liposome inhalation suspension (ALIS)
Trial: 37258803
Drug: Dapagliflozin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin (10 mg) + Sitagliptin (100 mg) + Metformin (1000 mg) ER
Trial: 37258803
Drug: Sitagliptin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin (100 mg) + Metformin (1000 mg) SR
Trial: 37258803
Drug: Dapagliflozin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin (10 mg) + Metformin (1000 mg) ER
Trial: 37258803
Drug: Dapagliflozin +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin + Sitagliptin + Metformin ER
Trial: 34235909
Drug: InGaAsP and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: InGaAsP and Er,Cr:YSGG laser adjunctive to subgingival debridement
Trial: 39642783
Drug: Prolonged Exposure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged Exposure Therapy (PE)
Trial: 36103260
Drug: Levothyroxine 50mcg
RxNorm normalized name: LEVOTHYROXINE 50MCG/ML ORAL SOLN UD
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Levothyroxine 50mcg daily
Trial: 32931996
Drug: Modified Mindfulness-Based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified Mindfulness-Based Cognitive Therapy (MBCT)
Trial: 32425802
Drug: Pimavanserin 34
RxNorm normalized name: pimavanserin 34 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pimavanserin 34 mg/day
Trial: 33993136
Drug: Enhanced oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced oral care (intervention units)
Trial: 33993136
Drug: Usual oral
RxNorm normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual oral care (control units)
Trial: 32325012
Drug: Oral antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antibiotics (ciprofloxacin 750 mg every 12 h and metronidazole 250 mg every 8 h the day before surgery)
Trial: 32325012
Drug: No oral
RxNorm normalized name: Beano Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No oral antibiotics (control group)
Trial: 32325012
Drug: Oral antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antibiotics (experimental group)
Trial: 32400732
Drug: Traditional massage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional massage in addition to routine physical therapy (once daily, five times a week for three months)
Trial: 32400732
Drug: Routine physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine physical therapy (once daily, five times a week for three months)
Trial: 35728048
Drug: Azacitidine monotherapy
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azacitidine monotherapy (n = 227)
Trial: 37070436
Drug: Placebo (once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (once daily for 12 weeks)
Trial: 32902668
Drug: Submucosal dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Submucosal dexamethasone (8 mg)
Trial: 36098362
Drug: Metformin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin plus Bifidobacterium animalis subsp. lactis (BB‐12) probiotic (MET-PRO group)
Trial: 36098362
Drug: Metformin alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin alone (MET group)
Trial: 33811308
Drug: Sulpiride (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulpiride (200 mg)
Trial: 36181480
Drug: 100-mg testosterone
RxNorm normalized name: testosterone 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100-mg testosterone cypionate (weekly intramuscular injections)
Trial: 36181480
Drug: Placebo (weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (weekly intramuscular injections)
Trial: 34452930
Drug: Ipilimumab 10
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ipilimumab 10 mg/kg every 3 weeks for four doses and then every 12 weeks
Trial: 34176722
Drug: CNSA-001 (sepiapterin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CNSA-001 (sepiapterin, PTC923) 10 mg/kg BID for 14 days
Trial: 35278283
Drug: Dupilumab 200
RxNorm normalized name: dupilumab 200 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dupilumab 200 mg administered via autoinjector (AI)
Trial: 35278283
Drug: Dupilumab 200
RxNorm normalized name: dupilumab 200 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dupilumab 200 mg administered via prefilled syringe with needle shield (PFS-S)
Trial: 32363743
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg enalapril and 0.8 mg folic acid
Trial: 32363743
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg enalapril alone
Trial: 33291649
Drug: 0.6 L/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 L/day of an artificially sweetened soft drink containing acesulfame K (950) and aspartame (951) for 2 weeks
Trial: 33291649
Drug: 0.6 L/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 L/day of mineral water for 2 weeks
Trial: 33671093
Drug: LEA with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LEA with low protein (LEA-LP; 0.8 g protein·kg BW-1)
Trial: 33671093
Drug: LEA with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LEA with high protein (LEA-HP; 1.7 g protein·kg BW-1)
Trial: 33671093
Drug: Control (CON;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (CON; 40 kcal·kg FFM-1·day-1, 1.7 g protein·kg BW-1)
Trial: 33087055
Drug: Selenium (L‐selenomethionine)
DrugBank: Selenium (DB11135)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenium (L‐selenomethionine) 200 μg/day for 3 months
Trial: 33087055
Drug: Control (nothing,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (nothing, in addition to recommended therapy)
Trial: 35665800
Drug: Precision prevention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Precision prevention materials incorporating melanocortin‐1 receptor genetic risk information
Trial: 33872587
Drug: Mepolizumab 100
RxNorm normalized name: mepolizumab 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mepolizumab 100 mg subcutaneously once every 4 weeks for 52 weeks
Trial: 33745228
Drug: Unguided web-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unguided web-based cognitive behavioral therapy (CBT) program for IBS